共查询到20条相似文献,搜索用时 15 毫秒
1.
Neonatal invasive fungal infections (IFIs) remain an increasing problem associated with high rates of morbidity and mortality,
as well as late-onset neurodevelopmental implications. Invasive candidiasis remains the leading neonatal IFI. Candida albicans is the fungal species most often affecting this population, although a changing epidemiologic incidence to non- albicans Candida species is reported in some neonatal intensive care units. Many treatment recommendations are extrapolated from adult populations,
emphasizing the need to establish the optimal antifungal agent, dosage, and duration of therapy in neonates. Historically,
conventional amphotericin B has been considered an efficient and safe treatment approach for most neonatal IFIs. More recently,
lipid formulations of amphotericin B have been studied, used alone or in combination with other antifungal agents such as
azoles or echinocandins. The aim of this article is to review the published experience in the use of amphotericin B formulations
to treat neonatal IFIs. 相似文献
2.
Antifungal drug resistance significantly impacts treatment outcomes in patients with invasive fungal infections (IFIs). Although
primary (intrinsic) resistance may occur independent of previous therapy, prior concomitant antifungal exposure increases
the risk for secondary (acquired) resistance and subsequent colonization or infection with less-susceptible pathogens. Among
various pathogen-antifungal combinations, this effect has been best studied clinically with azole exposure and the risk of
Candida spp. with reduced susceptibility. The rapid development of secondary resistance to flucytosine in Candida spp. has limited its use as monotherapy. Secondary resistance to amphotericin B is infrequent. In contrast, secondary resistance
in Aspergillus spp. is less of a concern. Recent reports of secondary resistance in patients receiving fluconazole for cryptococcal infections
may justify susceptibility testing in the setting of prior therapy or treatment failure. Despite numerous patient-focused,
drug-focused, and disease-focused strategies to improve treatment outcomes, clinical resistance (manifesting as treatment
failures despite adequate antifungal therapy) continues to be problematic in patients with serious IFIs. 相似文献
3.
The management of invasive fungal infections (IFIs) remains a challenge to the most experienced clinicians and mycologists as the therapeutic landscape continues to change. Delegates to the 17th International Symposium on Infections in the Immunocompromised Host heard that fungal epidemiology, patient demographics, diagnosis and treatment are all evolving. Diagnosis-driven therapy—pre-emptive or targeted—is the ideal approach to managing IFIs, but is dependent on reliable biomarker assays to identify, or at least strongly suggest, the organism(s) responsible. Biomarkers, however, are subject to ongoing research and so are also evolving. Some assays also may not be available in a particular centre. The same applies to investigations such as CT-scans and bronchoscopy that need to be performed in a timely fashion to help confirm an IFI. Thus, for patients with febrile neutropenia despite broad-spectrum antibiotic cover, clinicians without the appropriate diagnostic facilities prefer to start antifungal (AF) treatment immediately whilst attempting to confirm the diagnosis. Empirical therapy therefore looks likely to have a role for some time. For high-risk patients, such as those with haematological malignancies and/or undergoing haematopoietic stem cell transplantation (HSCT), the preferred strategy is to prevent IFIs using AF prophylaxis although regular screening with biomarkers is an alternative. 相似文献
4.
The purpose of this review is to summarize and evaluate relevant literature on combination antifungal therapy for invasive fungal infections (IFIs). Cryptococcal meningitis has the largest body and highest quality in support of combination therapy with amphotericin B and flucytosine. More recent data in treatment of invasive aspergillosis suggest combination therapy with voriconazole and echinocandins may be effective in select patients. Quality studies are needed to define combination therapy in rare mold infections. Multiple strategies have been employed to optimize treatment of the growing incidence of IFIs. With exceptions as noted above, justification for the use of combination antifungal therapy is most often based on uncontrolled and/or underpowered studies, in vitro data, and case reports. 相似文献
5.
Although Zygomycetes, Fusarium spp, and Scedosporium spp are far less frequent causes of invasive fungal disease than Aspergillus and Candida, they are emerging. These types of infections in severely immunocompromised patients have a common feature: a poor clinical
response to antifungal therapy. Infection is usually airborne, although local infections in cases of skin trauma are also
possible. These fungi are resistant to some common antifungal agents; therefore, surgical debridement of the necrotic tissue,
when possible, should be combined with specific systemic antifungal treatment in immunocompromised patients. In the absence
of randomized clinical trials, most experience in the treatment of these infections is with amphotericin B. Experience with
new antifungal agents is still limited, and recovery from neutropenia remains the main predictor of a favorable outcome. 相似文献
6.
Invasive fungal infections (IFIs) pose the most serious infectious risk to patients with hematologic malignancies and in those
undergoing hematopoietic stem cell transplantation (HSCT). Invasive candidiasis has an incidence of 8–18% and a mortality
of 30–40% in various reports. Invasive aspergillosis has an incidence of 4–15% and an even higher mortality of 60–85% cited
in the published literature. IFIs have remained difficult to diagnose in a timely way in neutropenic and immunocompromised
patients. A timely diagnosis is essential in promptly initiating antifungal therapy in order to optimize clinical outcomes.
Thus, antifungal prophylaxis has an enormous appeal to minimize the threat from IFIs. In this article, the epidemiology and
risk factors for IFIs as well as evidence from antifungal prophylaxis clinical trials in certain patient groups with hematologic
malignancies are reviewed. Antifungal prophylaxis has been shown to be effective in certain settings. However, concerns about
shifts in fungal epidemiology, emergence of resistance, drug toxicities, and drug interactions must be considered in deciding
how and in whom to use antifungal prophylaxis. 相似文献
7.
随着免疫受损人群的增多,近年来侵袭性真菌感染的发生率逐渐升高,由此导致的致病率也逐年上升.如何及时诊断并有效的治疗侵袭性真菌感染已成为临床上面临的挑战之一.该文就侵袭性真菌感染的流行病学、病因学及现有的治疗策略等方面进行综述. 相似文献
8.
Candida infections are most prominent among fungal infections majorly target immunocompromised and hospitalized patients and cause significant morbidity and mortality. Candida albicans is the notorious and most prevalent among all pathogenic Candida strains. Its emerging resistance toward available antifungal agents making it hard to tackle and emerging as global healthcare emergency. Simultaneously, 1,2,3-triazole nucleus is a privileged scaffold that is gaining importance in antifungal drug development due to being a prominent bioactive linker and isostere of triazole based antifungal class core 1,2,4-triazole. Numerous reports have been updated in scientific literature in last few decades related to utilization of 1,2,3-triazole nucleus in antifungal drug development against Candida albicans. Present review will shed light on various preclinical studies focused on development of 1,2,3-triazole derivatives targeting Candida albicans along with brief highlight on clinical trials and newly approved drugs. Structure-activity relationship has been precisely discussed for each architect along with future perspective that will help medicinal chemists in design and development of potent antifungal agents for tackling infections derived from Candida albicans. 相似文献
9.
Purpose of ReviewThe incidence of systemic fungal infections is increasing among patients admitted to the intensive care unit (ICU). Acute kidney injury (AKI) occurs in one third of ICU patients and approximately 5% require renal replacement therapy (RRT). Among those requiring RRT, continuous RRT (CRRT) is used in more than 70% of cases. This review aims to summarize antifungal dosing management in ICU patients receiving CRRT.Recent FindingsFor most antifungal agents, including new azoles such as posaconazole and isavuconazole, CRRT does not significantly affect antifungal pharmacokinetics (PK) mainly due to drug liver elimination and high protein binding. For fluconazole, increased dose is recommended during CRRT taking into account the type of CRRT mode (CVVHF or CVVHDF), membrane surface, and effluent and dialysis flow rates. A dose increase for itraconazole seems also necessary during CRRT; a dose decrease for flucytosine is probably necessary but data are too scarce to give a strong recommendation.SummaryIn ICU patients receiving CRRT, no dosing adjustment is required for the majority of antifungal agents commonly used to treat invasive fungal infections (IFIs) excepted for fluconazole, itraconazole, and flucytosine. Due to high PK variability, therapeutic drug monitoring should be considered in ICU patients receiving CRRT. 相似文献
10.
The treatment of invasive fungal infections remains a challenge, both for the diagnosis and for the need of providing the appropriate antifungal therapy. Candida auris is a pathogenic yeast that is responsible for hospital outbreaks, especially in intensive care units; it is characterized by a high resistance to the antifungal agents and can become multidrug-resistant. At present, the recommended antifungal agents for the invasive infections with this pathogen are echinocandins, always after carrying out an antifungal susceptibility testing. In case of no clinical response or persistent candidemia, the addition of liposomal amphotericin B or isavuconazole may be considered. Both fungal infection of the central nervous system and that associated with biomedical devices remain rare entities affecting mainly immunocompromised patients. However, an increase in their incidence in recent years, along with high morbidity and mortality, has been shown. The treatment of these infections is conditioned by the limited knowledge of the pharmacokinetic properties of antifungals. A better understanding of the pharmacokinetic and pharmacodynamic parameters of the different antifungals is essential to determine the efficacy of the antifungal agents in the treatment of these infections. 相似文献
11.
Pulmonary infections caused by Aspergillus species are associated with significant morbidity and mortality in immunocompromised patients. Although the treatment of pulmonary fungal infections requires the use of systemic agents, aerosolized delivery is an attractive option in prevention because the drug can concentrate locally at the site of infection with minimal systemic exposure. Current clinical evidence
for the use of aerosolized delivery in preventing fungal infections is limited to amphotericin B products, although itraconazole,
voriconazole, and caspofungin are under investigation. Based on conflicting results from clinical trials that evaluated various
amphotericin B formulations, the routine use of aerosolized delivery cannot be recommended. Further research with well-designed
clinical trials is necessary to elucidate the therapeutic role and risks associated with aerosolized delivery of antifungal
agents. This article provides an overview of aerosolized delivery systems, the intrapulmonary pharmacokinetic properties of
aerosolized antifungal agents, and key findings from clinical studies. 相似文献
12.
Systemic candidiasis is one of the most common nosocomial systemic infections causing high mortality and morbidity. Although infections caused by other Candida species are increasing the majority of candidiasis is commonly caused by Candida albicans which accounts for 40–60% of the reported cases. Current antifungal treatment regime is feeble due to persistent multiple drug resistance. Moreover, antifungal agents are mostly synthetic drugs that cause toxic side effects on immune-compromised patients. So, not only finding novel drug candidates from natural sources is necessary but to identify such compounds that have multiple targeting potential is essential. Hence, in this study, we propose to screen and identify bioactive natural compounds based on flavonoids, terpenes, and alkaloids for their potential antifungal activity. This in silico study was carried out by targeting 16 major virulent protein targets of C. albicans with 91 ligands. We have reported few ligands having multi-targeting potential and further analyzed theirs in silico pharmacokinetic profile. In silico ADMET analysis and protein–protein interaction can not only help in refining better drug candidates but also shortlist ideal protein for drug targeting. 相似文献
13.
随着免疫功能缺陷人群的增多,侵袭性真菌感染(invasive fungal infections,IFIs)的发病率和死亡率逐年上升,严重威胁人类健康。目前临床常用抗侵袭性真菌感染药物有三唑类(氟康唑)、多烯类(两性霉素B)、棘白菌素类(卡泊芬净)等,然而这些药物并不能满足临床需要,侵袭性真菌感染的死亡率仍居高不下。因此,本文着重于目前处于临床研究阶段的抗真菌感染新药,根据作用靶点不同依次介绍:作用于细胞壁的新型葡聚糖合成酶抑制剂CD101和SCY-078、几丁质合成酶抑制剂尼可霉素Z、GPI锚定蛋白抑制剂APX001;作用于细胞膜的CYP51抑制剂VT-1161和VT-1129、破坏细胞膜通透性药物CAmB;影响细胞代谢的嘧啶合成抑制剂F901318,以及生物制剂包括细胞表面凝集素样序列3蛋白疫苗(NDV-3)和抗真菌感染抗体Mycograb。本文主要综述了上述新药的研究进展,包括作用机制、体内外活性、临床研究结果等,为相关药物的研发与未来的临床应用提供参考。 相似文献
14.
As fungal infections are becoming more prevalent in the medical or agricultural fields, novel and more efficient antifungal
agents are badly needed. Within the scope of developing new strategies for the management of fungal infections, antifungal
compounds that target essential fungal cell wall components are highly preferable. Ideally, newly developed antimycotics should
also combine major aspects such as sustainability, high efficacy, limited toxicity and low costs of production. A naturally
derived molecule that possesses all the desired characteristics is the antifungal protein (AFP) secreted by the filamentous
ascomycete Aspergillus giganteus. AFP is a small, basic and cysteine-rich peptide that exerts extremely potent antifungal activity against human- and plant-pathogenic
fungi without affecting the viability of bacteria, yeast, plant and mammalian cells. This review summarises the current knowledge
of the structure, mode of action and expression of AFP, and highlights similarities and differences concerning these issues
between AFP and its related proteins from other Ascomycetes. Furthermore, the potential use of AFP in the combat against fungal
contaminations and infections will be discussed. 相似文献
15.
Fungal infection represents a severe problem that decreases the yield and market value of fruit crops. The use of fungicides is a conventional method to control infections but it is associated with disadvantages, such as hazardous impact on public health, environmental contamination, resistance development among pathogens and high cost of agrochemicals. Biological control is an alternative approach for the treatment of fungal infections. The species of Bacillus, Pseudomonas, Enterobacter, Pantoea, Burkholderia, Lysobacter and Serratia have been successfully used in the control of fungal infections. The mechanisms involved in biocontrol are hyperparasitism or predation, production of antibiotics, lytic enzymes and induction of host resistance. Lactic acid bacteria have been used as biopreservative organisms in food and feed systems. They are a cluster of Gram-positive bacteria and include species of the genera Enterococcus, Lactobacillus, Leuconostoc, Lactococcus and Pediococcus. The ability to produce several antibacterial and antifungal substances confers biopreservation potential to lactic acid bacteria. Many have ‘generally regarded as safe’ status and are considered as safe from both human and environmental points of view. Their isolation is reported from vegetables, aerial plant surfaces, pickled cabbage, grass silage, malted cereals and also from soil. They produce antifungal substances, such as cyclic dipeptides, proteinaceous compounds, organic acids, fatty acids and reuterin. The biocontrol potential of lactic acid bacteria is demonstrated in the prevention of fungal infections of fruits, such as apples and grapes. Thus, living cells or product formulations of antifungal lactic acid bacteria may be prepared and used as an alternative biocontrol technology. 相似文献
16.
Candida albicans is the most virulent Candida species of medical importance, which presents a great threat to immunocompromised individuals such as HIV patients. Currently,
there are only four classes of antifungal agents available for treating fungal infections: azoles, polyenes, pyrimidines,
and echinocandins. The fast spread of multidrug resistant C. albicans strains has increased the demand for new antifungal drugs. In this study, we demonstrate the antifungal activity of brominated
furanones on C. albicans. Studying the structure and activity of this class of furanones reveals that the exocyclic vinyl bromide conjugated with
the carbonyl group is the most important structural element for fungal inhibition. Furthermore, gene expression analysis using
DNA microarrays showed that 3 μg/mL of 4-bromo-5Z-(bromomethylene)-3-butylfuran-2-one (BF1) upregulated 32 C. albicans genes with functions of stress response, NADPH dehydrogenation, and small-molecule transport, and repressed 21 genes involved
mainly in cell-wall maintenance. Interestingly, only a small overlap is observed between the gene expression changes caused
by the representative brominated furanone (BF1) in this study and other antifungal drugs reported in literature. This result
suggests that brominated furanones and other antifungal drugs may target different fungal proteins or genes. The existence
of such new targets provides an opportunity for developing new agents to control fungal pathogens which are resistant to currently
available drugs. 相似文献
17.
The second-generation triazoles, voriconazole and posaconazole, have found important roles in the management of invasive fungal
infections in high-risk patients. Both agents are more active against Candida albicans and the non- albicans Candida species than the first-generation triazoles. They are active against Aspergillus species, including those species less susceptible to polyenes, and against a variety of non- Aspergillus molds. In contrast to posaconazole, voriconazole has no activity against the zygomycetes, and breakthrough infections have
been observed. Both are well absorbed, but considerable intra- and interpatient pharmacokinetic variability has raised the
question of therapeutic drug monitoring. Both inhibit hepatic cytochrome P450 isoenzymes, which are important in the metabolism
of various drugs coadministered in the management of high-risk patients. Clinical trials have demonstrated the safety and
efficacy of both agents for antifungal prophylaxis and treatment in invasive candidiasis, invasive aspergillosis, and in invasive
fungal infections caused by a variety of non- Aspergillus molds. Posaconazole is the only triazole approved for use in the treatment of invasive zygomycosis. Voriconazole is the accepted
standard first-line therapy for invasive aspergillosis. 相似文献
18.
Invasive fungal diseases (IFDs) remain a major cause of morbidity and mortality in allogeneic stem cell transplant (SCT) recipients.
While the most common pathogens are Candida spp. and Aspergillus spp., the incidence of infections caused by non- albicans Candida species as well as molds such as Zygomycetes has increased. For many years, amphotericin B deoxycholate (AMB-D) was the only
available antifungal for the treatment of IFDs. Within the past decade, there has been a surge of new antifungal agents developed
and added to the therapeutic armamentarium. Lipid-based formulations of amphotericin B provide an effective and less nephrotoxic
alternative to AMB-D. Voriconazole has now replaced AMB-D as first choice for primary therapy of invasive aspergillosis (IA).
Another extended-spectrum triazole, posaconazole, also appears to be a promising agent in the management of zygomycosis, refractory
aspergillosis, and for prophylaxis. Members of the newest antifungal class, the echinocandins, are attractive agents in select
infections due to their safety profile, and are a more attractive option compared to AMB-D as initial treatment for invasive
candidiasis and (based on one study) challenge fluconazole for superiority in management with this mycoses. However, challenges
do exist among these newer agents in very high-risk individuals like allogeneic SCT recipients, which may include adverse
drug events, drug–drug interactions, variability in oral absorption, and availability of alternative formulations. The addition
of newer agents has also stimulated interest in the potential application of combination therapy in serious, life-threatening
infections. However, adequate studies are not available for most IFDs; thus, the clinical use of combination therapy is not
evidenced based on most cases and preciseness in its use is uncertain. Finally, therapeutic drug monitoring of select antifungals
(notably posaconazole and voriconazole) may play an increasing role due to significant interpatient variability in serum concentrations
after standard doses. 相似文献
19.
The morbidity, mortality and economic burden associated with fungal infections, together with the emergence of fungal strains resistant to current antimicrobial agents, necessitate broadening our understanding of fungal pathogenesis and discovering new agents to treat these infections. Using invertebrate hosts, especially the nematode Caenorhabditis elegans and the model insects Drosophila melanogaster and Galleria mellonella, could help achieve these goals. The evolutionary conservation of several aspects of the innate immune response between invertebrates and mammals makes the use of these simple hosts an effective and fast screening method for identifying fungal virulence factors and testing potential antifungal compounds. The purpose of this review is to compare several model hosts that have been used in experimental mycology to-date and to describe their different characteristics and contribution to the study of fungal virulence and the detection of compounds with antifungal properties. This article is part of a Special Issue entitled: Animal Models of Disease. 相似文献
20.
Breakthrough invasive infections occur in immunosuppressed patients while they are receiving antifungal agents for both prophylaxis and therapy. Under such conditions, unusual fungal infections emerge. Hormographiella aspergillata is considered an uncommon human pathogen and causes devastating infections. Here, we present a case report of necrotizing pneumonia caused by H. aspergillata as a breakthrough infection in a neutropenic patient and review all previous cases of H. aspergillata infection reported in the literature. 相似文献
|